{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:37:13Z","timestamp":1765949833494,"version":"3.48.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00520-025-10070-2","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:32:29Z","timestamp":1763364749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A modelled cost-utility analysis comparing early referral to specialist palliative care versus standard care for older people with acute myeloid leukaemia"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6792-7367","authenticated-orcid":false,"given":"Elise","family":"Button","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-3723","authenticated-orcid":false,"given":"Nikki","family":"McCaffrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-4126","authenticated-orcid":false,"given":"Hannah","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"1","key":"10070_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M et al (2020) The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol 13(1):1\u201316","journal-title":"J Hematol Oncol"},{"key":"10070_CR2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/CEOR.S187409","volume":"11","author":"A Forsythe","year":"2019","unstructured":"Forsythe A et al (2019) Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review. ClinicoEconomics and Outcomes Research: CEOR 11:87","journal-title":"ClinicoEconomics and Outcomes Research: CEOR"},{"issue":"10","key":"10070_CR3","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1016\/S2352-3026(20)30279-9","volume":"7","author":"A Berm\u00fadez","year":"2020","unstructured":"Berm\u00fadez A, Colorado M (2020) A glimmer of hope for older people with acute myeloid leukaemia. Lancet Haematol 7(10):e700\u2013e701","journal-title":"Lancet Haematol"},{"key":"10070_CR4","unstructured":"Australian Institute of Health and Welfare (2021) Cancer in Australia 2021. Cancer series no.133. Australian institure of health and welfare, Canberra, Australia. https:\/\/www.aihw.gov.au\/getmedia\/0ea708eb-dd6e-4499-9080-1cc7b5990e64\/aihw-can-144.pdf.aspx?inline=true.\u00a0Accessed 5 Feb 2022"},{"issue":"10","key":"10070_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-00964-1","volume":"22","author":"M Abdallah","year":"2020","unstructured":"Abdallah M et al (2020) Management of acute myeloid leukemia (AML) in older patients. Curr Oncol Rep 22(10):1\u201314","journal-title":"Curr Oncol Rep"},{"key":"10070_CR6","unstructured":"Cancer Council Victoria (2021) Optimal care pathway for people with acute myeloid leukaemia, 2nd edn. Department of health, Victoria, Australia.\u00a0https:\/\/www.cancer.org.au\/assets\/pdf\/acute-myeloid-leukaemia-optimal-cancer-care-pathway. Accessed 2 Oct 2022"},{"key":"10070_CR7","unstructured":"eviQ (2022) Actue myeloid leukaemia treatment protocols. NSW Cancer Institute, Australia. https:\/\/www.eviq.org.au\/haematology-and-bmt\/leukaemias\/acute-myeloid-leukaemia\/3892-acute-myeloid-leukaemia-azacitidine-and-venet. Accessed 22 Sept 2022"},{"issue":"6","key":"10070_CR8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11899-019-00552-6","volume":"14","author":"KP Loh","year":"2019","unstructured":"Loh KP et al (2019) Health-related quality of life and treatment of older adults with acute myeloid leukemia: a Young International Society of Geriatric Oncology review paper. Curr Hematol Malign Rep 14(6):523\u2013535","journal-title":"Curr Hematol Malign Rep"},{"issue":"11","key":"10070_CR9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/ajh.25975","volume":"95","author":"EH Estey","year":"2020","unstructured":"Estey EH (2020) Acute myeloid leukemia: 2021 update on risk-stratification and management. Am J Hematol 95(11):1368\u20131398","journal-title":"Am J Hematol"},{"key":"10070_CR10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ctrv.2018.07.005","volume":"69","author":"R Bosshard","year":"2018","unstructured":"Bosshard R et al (2018) Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia. Cancer Treat Rev 69:224\u2013232","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10070_CR11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/17474086.2019.1627869","volume":"12","author":"JP Bewersdorf","year":"2019","unstructured":"Bewersdorf JP et al (2019) Healthcare expenses for treatment of acute myeloid leukemia. Expert Rev Hematol 12(8):641\u2013650","journal-title":"Expert Rev Hematol"},{"key":"10070_CR12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/JBM.S279736","volume":"12","author":"A Forsythe","year":"2021","unstructured":"Forsythe A, Sandman K (2021) What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations. J Blood Med 12:245","journal-title":"J Blood Med"},{"key":"10070_CR13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2018.06.010","volume":"71","author":"JA Bell","year":"2018","unstructured":"Bell JA et al (2018) Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res 71:27\u201333","journal-title":"Leuk Res"},{"issue":"10","key":"10070_CR14","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41375-019-0449-1","volume":"33","author":"A El-Jawahri","year":"2019","unstructured":"El-Jawahri A et al (2019) Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia 33(10):2393\u20132402","journal-title":"Leukemia"},{"issue":"2","key":"10070_CR15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bmjspcare-2014-000793","volume":"7","author":"D Howell","year":"2017","unstructured":"Howell D et al (2017) Preferred and actual place of death in haematological malignancy. BMJ Support Palliat Care 7(2):150\u2013157","journal-title":"BMJ Support Palliat Care"},{"issue":"1","key":"10070_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-684X-9-9","volume":"9","author":"DA Howell","year":"2010","unstructured":"Howell DA et al (2010) Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. BMC Palliat Care 9(1):1\u20138","journal-title":"BMC Palliat Care"},{"issue":"1","key":"10070_CR17","first-page":"111","volume":"23","author":"H-WB Cheng","year":"2015","unstructured":"Cheng H-WB et al (2015) End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia. Support Care Cancer 23(1):111\u2013116","journal-title":"Support Care Cancer"},{"key":"10070_CR18","unstructured":"WHO (2022) Palliative care. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/palliative-care.\u00a0Accessed 7 Feb 2022"},{"key":"10070_CR19","unstructured":"Palliative Care Australia. What is palliative care? 2022, Available from: https:\/\/palliativecare.org.au\/resource\/what-is-palliative-care\/. Accessed 7 Feb 2022"},{"issue":"1","key":"10070_CR20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0269216317735246","volume":"32","author":"D Moreno-Alonso","year":"2018","unstructured":"Moreno-Alonso D et al (2018) Palliative care in patients with haematological neoplasms: an integrative systematic review. Palliat Med 32(1):79\u2013105","journal-title":"Palliat Med"},{"issue":"5","key":"10070_CR21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0269216318824489","volume":"33","author":"E Button","year":"2019","unstructured":"Button E et al (2019) A palliative care model and conceptual approach suited to clinical malignant haematology. Palliat Med 33(5):483\u2013485","journal-title":"Palliat Med"},{"issue":"8","key":"10070_CR22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1200\/JCO.2016.70.5046","volume":"35","author":"JS Temel","year":"2017","unstructured":"Temel JS et al (2017) Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial. J Clin Oncol 35(8):834","journal-title":"J Clin Oncol"},{"issue":"8","key":"10070_CR23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","volume":"363","author":"JS Temel","year":"2010","unstructured":"Temel JS et al (2010) Early palliative care for patients with metastatic non\u2013small-cell lung cancer. N Engl J Med 363(8):733\u2013742","journal-title":"N Engl J Med"},{"issue":"7","key":"10070_CR24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jama.2009.1198","volume":"302","author":"M Bakitas","year":"2009","unstructured":"Bakitas M et al (2009) Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 302(7):741\u2013749","journal-title":"JAMA"},{"issue":"13","key":"10070_CR25","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1200\/JCO.2014.58.6362","volume":"33","author":"MA Bakitas","year":"2015","unstructured":"Bakitas MA et al (2015) Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33(13):1438","journal-title":"J Clin Oncol"},{"issue":"9930","key":"10070_CR26","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","volume":"383","author":"C Zimmermann","year":"2014","unstructured":"Zimmermann C et al (2014) Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 383(9930):1721\u20131730","journal-title":"Lancet"},{"issue":"1","key":"10070_CR27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/10499091211011138","volume":"39","author":"A Parackal","year":"2022","unstructured":"Parackal A, Ramamoorthi K, Tarride J-E (2022) Economic evaluation of palliative care interventions: a review of the evolution of methods from 2011 to 2019. Am J Hosp Palliat Med 39(1):108\u2013122","journal-title":"Am J Hosp Palliat Med"},{"issue":"4","key":"10070_CR28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/bmjspcare-2020-002386","volume":"10","author":"S Tanzi","year":"2020","unstructured":"Tanzi S et al (2020) Early palliative care in haematological patients: a systematic literature review. BMJ Support Palliat Care 10(4):395\u2013403","journal-title":"BMJ Support Palliat Care"},{"key":"10070_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-002898","author":"L Potenza","year":"2021","unstructured":"Potenza L et al (2021) Early palliative\/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study. BMJ Support Palliat Care. https:\/\/doi.org\/10.1136\/bmjspcare-2021-002898","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"10070_CR30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamaoncol.2020.6343","volume":"7","author":"A El-Jawahri","year":"2021","unstructured":"El-Jawahri A et al (2021) Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial. JAMA Oncol 7(2):238\u2013245","journal-title":"JAMA Oncol"},{"key":"10070_CR31","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321001732","author":"D Husereau","year":"2022","unstructured":"Husereau D et al (2022) Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care. https:\/\/doi.org\/10.1017\/S0266462321001732","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"10070_CR32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jgo.2020.07.002","volume":"12","author":"K Sharplin","year":"2021","unstructured":"Sharplin K et al (2021) Outcomes and health care utilization of older patients with acute myeloid leukemia. J Geriatr Oncol 12(2):243\u2013249","journal-title":"J Geriatr Oncol"},{"key":"10070_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106742","volume":"104","author":"N McCaffrey","year":"2022","unstructured":"McCaffrey N et al (2022) A systematic review of economic evaluations of preoperative smoking cessation for preventing surgical complications. Int J Surg 104:106742","journal-title":"Int J Surg"},{"key":"10070_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2025.105319","author":"Q Xia","year":"2025","unstructured":"Xia Q et al (2025) Growth and changing landscape of the cost-utility literature: an Australian perspective, 1992\u20132022. Health Policy. https:\/\/doi.org\/10.1016\/j.healthpol.2025.105319","journal-title":"Health Policy"},{"key":"10070_CR35","unstructured":"TreeAge Pro (Version 2024 R2) (2024) TreeAge Software. Williamstronwn"},{"issue":"11","key":"10070_CR36","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1007\/s11136-024-03734-9","volume":"33","author":"E Button","year":"2024","unstructured":"Button E et al (2024) A systematic review of health state utility values for older people with acute myeloid leukaemia. Qual Life Res 33(11):2899\u20132914","journal-title":"Qual Life Res"},{"issue":"3","key":"10070_CR37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126(3):291\u2013299","journal-title":"Blood"},{"issue":"4","key":"10070_CR38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.leu.2403289","volume":"18","author":"M Sekeres","year":"2004","unstructured":"Sekeres M et al (2004) Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18(4):809\u2013816","journal-title":"Leukemia"},{"issue":"4","key":"10070_CR39","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jgo.2020.11.001","volume":"12","author":"J Ihlow","year":"2021","unstructured":"Ihlow J et al (2021) Clinical outcome of older adults with acute myeloid leukemia: an analysis of a large tertiary referral center over two decades. J Geriatr Oncol 12(4):540\u2013549","journal-title":"J Geriatr Oncol"},{"issue":"24","key":"10070_CR40","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood.2020005651","volume":"135","author":"B L\u00f6wenberg","year":"2020","unstructured":"L\u00f6wenberg B, Huls G (2020) The long road: improving outcome in elderly \u201cunfit\u201d AML? Blood 135(24):2114\u20132115","journal-title":"Blood"},{"issue":"1","key":"10070_CR41","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3747\/co.21.1311","volume":"21","author":"A Levy","year":"2014","unstructured":"Levy A et al (2014) Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes. Curr Oncol 21(1):e29","journal-title":"Curr Oncol"},{"issue":"4","key":"10070_CR42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2141.1998.00635.x","volume":"100","author":"UD Groot","year":"1998","unstructured":"Groot UD (1998) Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia. Br J Haematol 100(4):629\u2013636","journal-title":"Br J Haematol"},{"issue":"6","key":"10070_CR43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13696998.2019.1584108","volume":"22","author":"LS Matza","year":"2019","unstructured":"Matza LS et al (2019) Health state utilities associated with treatment options for acute myeloid leukemia. J Med Econ 22(6):567\u2013576","journal-title":"J Med Econ"},{"issue":"6","key":"10070_CR44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/ejh.13399","volume":"104","author":"EB Lennmyr","year":"2020","unstructured":"Lennmyr EB et al (2020) Introducing patient-reported outcome in the acute leukemia quality registries in Sweden. Eur J Haematol 104(6):571\u2013580","journal-title":"Eur J Haematol"},{"issue":"20","key":"10070_CR45","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.2016.16786","volume":"316","author":"A El-Jawahri","year":"2016","unstructured":"El-Jawahri A et al (2016) Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA 316(20):2094\u20132103","journal-title":"JAMA"},{"issue":"32","key":"10070_CR46","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1200\/JCO.2017.73.2800","volume":"35","author":"A El-Jawahri","year":"2017","unstructured":"El-Jawahri A et al (2017) Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial. J Clin Oncol 35(32):3714","journal-title":"J Clin Oncol"},{"issue":"3","key":"10070_CR47","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2013.06.011","volume":"130","author":"WJ Lowery","year":"2013","unstructured":"Lowery WJ et al (2013) Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 130(3):426\u2013430","journal-title":"Gynecol Oncol"},{"key":"10070_CR48","doi-asserted-by":"crossref","unstructured":"Kuntz K, Russell B, Owens D, Sanders G, Trikalinos T, Salomon J (2017) Decision models in cost-effectiveness analysis. In: Neuman P, Sanders G, Russell L, Siegel J, Ganiats T (eds) Cost-effectiveness in health and medicine, 2nd edn. Oxford, New York, pp 105\u2013135","DOI":"10.1093\/acprof:oso\/9780190492939.003.0005"},{"key":"10070_CR49","doi-asserted-by":"crossref","unstructured":"Owens D, Siegel J, Sculpher M, Salomon J (2017) Designing a cost-effective analyssis. In: Neuberg D, Sanders G, Russell B, Siegel J, Ganiats T (eds) Cost-effectiveness in health and medicine, 2nd edn. Oxford, New York, pp 75\u2013104","DOI":"10.1093\/acprof:oso\/9780190492939.003.0004"},{"key":"10070_CR50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","volume":"17","author":"AH Briggs","year":"2000","unstructured":"Briggs AH (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479\u2013500","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10070_CR51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","volume":"10","author":"A Peterson","year":"2007","unstructured":"Peterson A et al (2007) International Society for Pharmacoeconomics and Outcomes Research (ISPOR): a checklist for medication compliance and persistence studies using retrospective databases. Value Health 10(1):3\u201312","journal-title":"Value Health"},{"issue":"7202","key":"10070_CR52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/bmj.319.7202.120","volume":"319","author":"A Briggs","year":"1999","unstructured":"Briggs A (1999) Handling uncertainty in economic evaluation. BMJ 319(7202):120","journal-title":"BMJ"},{"issue":"10","key":"10070_CR53","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jval.2021.04.1286","volume":"24","author":"HE Carter","year":"2021","unstructured":"Carter HE et al (2021) Cost-effectiveness of a serum biomarker test for risk-stratified liver ultrasound screening for hepatocellular carcinoma. Value Health 24(10):1454\u20131462","journal-title":"Value Health"},{"key":"10070_CR54","doi-asserted-by":"crossref","unstructured":"Xia Q, Senanayake SJ, Kularatna S, Brain D, McPhail SM, Parsonage W, Eastgate M, Barnes A, Brown N, Carter HE (2025) Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia. In: Urologic Oncology: Seminars and Original investigations, vol. 43, No 1. Elsevier, pp 62\u2013e15","DOI":"10.1016\/j.urolonc.2024.09.016"},{"issue":"1","key":"10070_CR55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12904-024-01516-1","volume":"23","author":"K Janke","year":"2024","unstructured":"Janke K et al (2024) A palliative care approach for adult non-cancer patients with life-limiting illnesses is cost-saving or cost-neutral: a systematic review of RCTs. BMC Palliat Care 23(1):200","journal-title":"BMC Palliat Care"},{"issue":"5","key":"10070_CR56","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1089\/jpm.2017.0463","volume":"21","author":"JR Lowe","year":"2018","unstructured":"Lowe JR et al (2018) A cohort study of patient-reported outcomes and healthcare utilization in acute myeloid leukemia patients receiving active cancer therapy in the last six months of life. J Palliat Med 21(5):592\u2013597","journal-title":"J Palliat Med"},{"key":"10070_CR57","unstructured":"KPMG (2020) Investing to save: the economics of increased investment in palliative care in Australia. Palliative Care Australia and KPMG, Australia. https:\/\/palliativecare.org.au\/publication\/kpmg-palliativecare-economic-report\/. Accessed 22 Sept 2022"},{"issue":"6","key":"10070_CR58","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/14737167.4.6.599","volume":"4","author":"RM Klok","year":"2004","unstructured":"Klok RM, Postma MJ (2004) Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant. Expert Rev Pharmacoecon Outcomes Res 4(6):599\u2013601","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10070_CR59","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jhealeco.2012.01.006","volume":"31","author":"J Round","year":"2012","unstructured":"Round J (2012) Is a QALY still a QALY at the end of life? J Health Econ 31(3):521\u2013527","journal-title":"J Health Econ"},{"issue":"6","key":"10070_CR60","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s11136-019-02114-y","volume":"28","author":"L Proud","year":"2019","unstructured":"Proud L, McLoughlin C, Kinghorn P (2019) ICECAP-O, the current state of play: a systematic review of studies reporting the psychometric properties and use of the instrument over the decade since its publication. Qual Life Res 28(6):1429\u20131439","journal-title":"Qual Life Res"},{"issue":"2","key":"10070_CR61","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jpainsymman.2016.02.012","volume":"52","author":"N McCaffrey","year":"2016","unstructured":"McCaffrey N et al (2016) What aspects of quality of life are important from palliative care patients\u2019 perspectives? A systematic review of qualitative research. J Pain Symptom Manage 52(2):318-328. e5","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"10070_CR62","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jpainsymman.2008.11.010","volume":"37","author":"N McCaffrey","year":"2009","unstructured":"McCaffrey N, Currow DC, Eckermann S (2009) Measuring impacts of value to patients is crucial when evaluating palliative care. J Pain Symptom Manage 37(6):e7\u2013e9","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"10070_CR63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40271-023-00651-w","volume":"17","author":"N McCaffrey","year":"2024","unstructured":"McCaffrey N et al (2024) What aspects of quality of life are important from palliative care patients\u2019 perspectives? A framework analysis to inform preference-based measures for palliative and end-of-life settings. The Patient-Patient-Centered Outcomes Research 17(1):39\u201352","journal-title":"The Patient-Patient-Centered Outcomes Research"},{"issue":"10","key":"10070_CR64","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","volume":"20","author":"AB Kornblith","year":"2002","unstructured":"Kornblith AB et al (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20(10):2441\u20132452","journal-title":"J Clin Oncol"},{"issue":"21","key":"10070_CR65","volume":"122","author":"N Batty","year":"2013","unstructured":"Batty N et al (2013) Decitabine is more cost effective than standard conventional induction therapy in elderly acute myeloid leukemia patients. Blood 122(21):2699","journal-title":"Blood"},{"issue":"21","key":"10070_CR66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2571.2571","volume":"116","author":"SA Ingber","year":"2010","unstructured":"Ingber SA et al (2010) The effects of azacitidine on quality of life measured longitudinally in MDS patients treated at a tertiary care center. Blood 116(21):2571","journal-title":"Blood"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10070-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10070-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10070-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:32:53Z","timestamp":1765949573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10070-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10070"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10070-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Elise Button: Conceptualisation, Methodology, Formal analysis, Writing \u2013original draft,\u00a0Project administration. Nikki McCaffrey: Conceptualisation, Methodology, Formal analysis,\u00a0Writing \u2013 original draft, Supervision. Thomas LeBlanc: Conceptualisation, Writing \u2013 review\u00a0and editing. Hannah Carter: Conceptualisation, Methodology, Formal analysis, Writing \u2013\u00a0original draft, Supervision.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1072"}}